NASDAQ: $BNTX An Important Update in Precision Oncology BioNTech SE has recently provided a clinical update regarding its Phase 2 trial of autogene cevumeran (BNT122), an investigational individualized mRNA-based cancer vaccine. The study focuses on patients with resected colorectal cancer who are at high risk of recurrence. Understanding the Trial Focus The Phase 2 trial…